Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Update

Alto Neuroscience, Inc. (NYSE:ANRO) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 3,270,000 shares, a growth of 6.9% from the August 31st total of 3,060,000 shares. Based on an average daily trading volume, of 279,600 shares, the short-interest ratio is presently 11.7 days. Currently, 14.7% of the shares of the company are sold short.

Analyst Ratings Changes

A number of analysts have recently commented on ANRO shares. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Wedbush reissued an “outperform” rating and issued a $29.00 price target on shares of Alto Neuroscience in a report on Tuesday, September 10th. Finally, Rodman & Renshaw started coverage on shares of Alto Neuroscience in a research report on Friday, June 21st. They issued a “buy” rating and a $43.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.80.

Insider Buying and Selling

In other news, insider Adam Savitz acquired 12,069 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was bought at an average price of $12.60 per share, with a total value of $152,069.40. Following the completion of the acquisition, the insider now owns 36,920 shares of the company’s stock, valued at $465,192. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds and other institutional investors have recently made changes to their positions in ANRO. Federated Hermes Inc. grew its holdings in shares of Alto Neuroscience by 33.3% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after purchasing an additional 3,000 shares during the period. Bowie Capital Management LLC purchased a new stake in shares of Alto Neuroscience in the 2nd quarter valued at approximately $462,000. TD Asset Management Inc acquired a new stake in shares of Alto Neuroscience during the 2nd quarter worth approximately $928,000. Rhumbline Advisers purchased a new stake in shares of Alto Neuroscience during the 2nd quarter valued at approximately $113,000. Finally, Bank of New York Mellon Corp acquired a new position in Alto Neuroscience in the second quarter valued at approximately $252,000.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $11.17 on Wednesday. Alto Neuroscience has a fifty-two week low of $7.91 and a fifty-two week high of $24.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85. The stock’s fifty day moving average is $11.79 and its two-hundred day moving average is $12.81.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.07. As a group, research analysts forecast that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.